AC
JSPR icon

Armistice Capital’s Jasper Therapeutics JSPR Stock Holding History

Armistice Capital’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-348,000
Closed -$828K – 431
2025
Q3 		$828K Buy
+348,000
New +$1.06M 0.01% 177

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Armistice Capital's JSPR Position: Q4 2025 in Review

Armistice Capital sold out of Jasper Therapeutics (JSPR) in Q4 2025, closing a stake of 348,000 shares — an estimated $828K sold.

Armistice Capital first reported a position in JSPR in Q3 2025 and held it in 1 quarter. The position peaked at $828K in Q3 2025. 55 funds tracked by Wall St. Rank hold JSPR as of Q4 2025.

  • Armistice Capital reported no remaining Jasper Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Armistice Capital sold 348,000 Jasper Therapeutics shares in Q4 2025, an estimated $828K.
  • Armistice Capital first reported a position in Jasper Therapeutics in Q3 2025 and held it in 1 quarter.
  • Armistice Capital's Jasper Therapeutics position peaked at $828K in Q3 2025.
  • 55 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q4 2025.

Based on Armistice Capital's 13F filing for Q4 2025, filed 17 Feb 2026.